compared with the proportion of patients with successful cleansing in the 2L PEG-3350 and bisacodyl tablets treatment arm
(84.2% vs 74.4%) (Table 2). P/MC was noninferior and to 2L PEG-3350 and bisacodyl tablets in overall
cleansing of the colon for patients in the ITT (Fig. 1 and Table 2) and PP (Table 3) populations. Segmental
cleansing was also noninferior and superior in all colonic segments for P/MC compared with 2L PEG-3350 and bisacodyl
tablets (Tables 2 and 3 and Fig. 2). The largest segmental difference in the proportion of patients with
successful cleansing was in the ascending colon (89.5% vs 78.8% for patients in the P/MC and 2L PEG-3350 and bisacodyl
tablets treatment arms, respectively).